A clinical prognostic scoring system for resectable gastric cancer to predict survival and benefit from paclitaxel- or oxaliplatin-based adjuvant chemotherapy

Autor: Qian J, Qian Y, Wang J, Gu B, Pei D, He S, Zhu F, Røe OD, Xu J, Liu L, Gu Y, Guo R, Yin Y, Shu Y, Chen X

Publikováno v: Drug Design, Development and Therapy, Vol 2016, Iss Issue 1, Pp 241-258 (2016)

Jing Qian,1,* Yingying Qian,1,* Jian Wang,1 Bing Gu,2,3 Dong Pei,1 Shaohua He,1 Fang Zhu,1 Oluf Dimitri Røe,4–7 Jin Xu,8 Lianke Liu,1 Yanhong Gu,1 Renhua Guo,1 Yongmei Yin,1 Yongqian Shu,1 Xiaofeng Chen1 1Department of Oncology, The First Affiliat

Externí odkaz: https://doaj.org/article/aa08a0a579104c99abf2ab1ad1275dd6

Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.

Promising microRNAs in pre-diagnostic serum associated with lung cancer up to eight years before diagnosis: a HUNT study.

Autor: Fotopoulos I; Department of Computer Science, University of Crete, 700 13, Heraklion, Crete, Greece., Nguyen OTD; Department of Clinical and Molecular Medicine, NTNU-Norwegian University of Science and Technology, Prinsesse Kristinas Gate 1, 7030, Trondheim, Norway.; Cancer Clinic, Levanger Hospital, Nord-Trøndelag Health Trust, Kirkegata 2, 7600, Levanger, Norway., Nøst TH; Department of Community Medicine, Faculty of Health Sciences, UiT The Arctic University of Norway, P.O. Box 6050 Langnes, 9037, Tromsø, Norway.; K.G. Jebsen Center for Genetic Epidemiology, Department of Public Health and Nursing, NTNU-Norwegian University of Science and Technology, Postboks 8905, 7491, Trondheim, Norway., Markaki M; Institute of Applied and Computational Mathematics, FORTH, 700 13, Heraklion, Crete, Greece., Lagani V; Institute of Chemical Biology, Ilia State University, 3/5, Kakuca Cholokashvili Ave, Tbilisi, Georgia.; Biological and Environmental Sciences and Engineering Division (BESE), King Abdullah University of Science and Technology KAUST, Thuwal, Saudi Arabia.; SDAIA-KAUST Center of Excellence in Data Science and Artificial Intelligence, 23952, Thuwal, Saudi Arabia., Mjelle R; Department of Clinical and Molecular Medicine, NTNU-Norwegian University of Science and Technology, Prinsesse Kristinas Gate 1, 7030, Trondheim, Norway.; K.G. Jebsen Center for Genetic Epidemiology, Department of Public Health and Nursing, NTNU-Norwegian University of Science and Technology, Postboks 8905, 7491, Trondheim, Norway.; Bioinformatics Core Facility, NTNU-Norwegian University of Science and Technology, 7491, Trondheim, Norway., Sandanger TM; Department of Community Medicine, Faculty of Health Sciences, UiT The Arctic University of Norway, P.O. Box 6050 Langnes, 9037, Tromsø, Norway., Sætrom P; Department of Clinical and Molecular Medicine, NTNU-Norwegian University of Science and Technology, Prinsesse Kristinas Gate 1, 7030, Trondheim, Norway.; K.G. Jebsen Center for Genetic Epidemiology, Department of Public Health and Nursing, NTNU-Norwegian University of Science and Technology, Postboks 8905, 7491, Trondheim, Norway.; Bioinformatics Core Facility, NTNU-Norwegian University of Science and Technology, 7491, Trondheim, Norway.; Department of Computer Science, Norwegian University of Science and Technology, 7491, Trondheim, Norway., Tsamardinos I; Department of Computer Science, University of Crete, 700 13, Heraklion, Crete, Greece.; Institute of Applied and Computational Mathematics, FORTH, 700 13, Heraklion, Crete, Greece.; JADBio Gnosis DA S.A., STEP-C, N. Plastira 100, 700-13, Heraklion, Greece., Røe OD; Department of Clinical and Molecular Medicine, NTNU-Norwegian University of Science and Technology, Prinsesse Kristinas Gate 1, 7030, Trondheim, Norway. oluf.roe@ntnu.no.; Cancer Clinic, Levanger Hospital, Nord-Trøndelag Health Trust, Kirkegata 2, 7600, Levanger, Norway. oluf.roe@ntnu.no.; Department of Oncology and Clinical Cancer Research Center, Aalborg University Hospital, 9000, Aalborg, Denmark. oluf.roe@ntnu.no.; Department of Clinical Medicine, Aalborg University Hospital, 9000, Aalborg, Denmark. oluf.roe@ntnu.no.

Publikováno v: Journal of cancer research and clinical oncology [J Cancer Res Clin Oncol] 2024 Jul 20; Vol. 150 (7), pp. 355. Date of Electronic Publication: 2024 Jul 20.

Impact of Prosigna test on adjuvant treatment decision in lymph node-negative early breast cancer-a prospective national multicentre study (EMIT-1).

Autor: Ohnstad HO; Department of Oncology, Division of Cancer Medicine, Oslo University Hospital, Oslo., Blix ES; Department of Oncology, University of North Norway, Tromsø; Department of Clinical Medicine, UiT The Arctic University of Norway, Tromsø., Akslen LA; Centre for Cancer Biomarkers CCBIO, Department of Clinical Medicine, Section for Pathology, University of Bergen, Bergen; Department of Pathology Haukeland University Hospital, Bergen., Gilje B; Department of Haematology and Oncology, Stavanger University Hospital, Stavanger., Raj SX; Department of Oncology, St Olavs Hospital, Trondheim., Skjerven H; Department of Breast Surgery, Vestre Viken Hospital Trust, Drammen., Borgen E; Department of Pathology, Division of Laboratory Medicine, Oslo University Hospital, Oslo., Janssen EAM; Department of Pathology, Stavanger University Hospital, Stavanger; Department of Chemistry, Bioscience and Environmental Engineering, Stavanger University, Stavanger, Norway; Menzies Health Institute Queensland and Griffith University, Southport, Australia., Mortensen E; Department of Pathology, University of North Norway, Tromsø., Brekke MB; Department of Pathology, St Olavs Hospital, Trondheim., Falk RS; Oslo Centre for Biostatistics and Epidemiology, Oslo University Hospital, Oslo., Schlichting E; Department of Oncology, Breast and Endocrine Surgery Unit, Division of Cancer Medicine, Oslo University Hospital, Oslo., Boge B; Department of Oncology, Hospital of Southern Norway, Kristiansand., Songe-Møller S; Department of Oncology, Østfold Hospital Trust, Kalnes., Olsson P; Department of Breast Surgery, Innlandet Hospital Trust, Hamar., Heie A; Department of Breast Surgery, Haukeland University Hospital, Bergen., Mannsåker B; Department of Oncology, Nordland Hospital, Bodø., Vestlid MA; Department of Breast Surgery, Telemark Hospital Trust, Skien., Kursetgjerde T; Department of Oncology, Møre og Romsdal Hospital Trust, Ålesund., Gravdehaug B; Department of Breast Surgery, Akershus University Hospital, Lørenskog., Suhrke P; Department of Pathology, Vestfold Hospital Trust, Tønsberg., Sanchez E; Department of Oncology, Haugesund Hospital, Haugesund., Bublevic J; Department of Oncology, Førde Central Hospital, Førde., Røe OD; Department of Oncology, Levanger Hospital, Levanger., Geitvik GA; Department of Cancer Genetics, Institute for Cancer Research, Oslo University Hospital, Oslo., Halset EH; Department of Oncology, Division of Cancer Medicine, Oslo University Hospital, Oslo., Rypdal MC; Department of Pathology, Division of Laboratory Medicine, Oslo University Hospital, Oslo., Langerød A; Department of Cancer Genetics, Institute for Cancer Research, Oslo University Hospital, Oslo., Lømo J; Department of Pathology, Division of Laboratory Medicine, Oslo University Hospital, Oslo., Garred Ø; Department of Pathology, Division of Laboratory Medicine, Oslo University Hospital, Oslo., Porojnicu A; Department of Oncology, Vestre Viken Hospital Trust, Drammen., Engebraaten O; Department of Oncology, Division of Cancer Medicine, Oslo University Hospital, Oslo; Institute of Clinical Medicine, University of Oslo, Oslo., Geisler J; Institute of Clinical Medicine, University of Oslo, Oslo; Department of Oncology, Akershus University Hospital, Lørenskog., Lyngra M; Department of Pathology, Akershus University Hospital, Lørenskog., Hansen MH; Department of Breast Surgery, University of North Norway, Tromsø., Søiland H; Department of Research, Stavanger University Hospital, Stavanger; Department of Clinical Science, University of Bergen, Bergen., Nakken T; User representative, Oslo University Hospital, Oslo., Asphaug L; Clinical Trials Unit, Oslo University Hospital, Oslo; Institute of Health and Society, Faculty of Medicine, University of Oslo, Oslo., Kristensen V; Institute of Clinical Medicine, University of Oslo, Oslo., Sørlie T; Department of Cancer Genetics, Institute for Cancer Research, Oslo University Hospital, Oslo; Institute of Clinical Medicine, University of Oslo, Oslo., Nygård JF; Cancer Registry of Norway, Oslo., Kiserud CE; National Advisory Unit for Late Effects after Cancer Treatment, Oslo University Hospital, Oslo, Norway., Reinertsen KV; Department of Oncology, Division of Cancer Medicine, Oslo University Hospital, Oslo; National Advisory Unit for Late Effects after Cancer Treatment, Oslo University Hospital, Oslo, Norway., Russnes HG; Department of Pathology, Division of Laboratory Medicine, Oslo University Hospital, Oslo; Department of Cancer Genetics, Institute for Cancer Research, Oslo University Hospital, Oslo; Institute of Clinical Medicine, University of Oslo, Oslo., Naume B; Department of Oncology, Division of Cancer Medicine, Oslo University Hospital, Oslo; Institute of Clinical Medicine, University of Oslo, Oslo. Electronic address: BNa@ous-hf.no.

Publikováno v: ESMO open [ESMO Open] 2024 Jun; Vol. 9 (6), pp. 103475. Date of Electronic Publication: 2024 Jun 04.

Exon 20-Mutated NSCLC: Extending the Data Set to Allow the Recognition of Potential Causes.

Autor: van Zandwijk N; Royal Prince Alfred Hospital, Sydney Local Health District, Camperdown, Australia., Amos CI; Royal Prince Alfred Hospital, Sydney Local Health District, Camperdown, Australia., Røe OD; Royal Prince Alfred Hospital, Sydney Local Health District, Camperdown, Australia., Reid G; Royal Prince Alfred Hospital, Sydney Local Health District, Camperdown, Australia., Klebe S; Royal Prince Alfred Hospital, Sydney Local Health District, Camperdown, Australia.

Publikováno v: JTO clinical and research reports [JTO Clin Res Rep] 2023 Mar 15; Vol. 4 (4), pp. 100500. Date of Electronic Publication: 2023 Mar 15 (Print Publication: 2023).